|Day Low/High||75.20 / 75.96|
|52 Wk Low/High||60.32 / 80.74|
Jim Cramer weighs in on Arena Pharmaceuticals, DaVita, Merck, Abbott Laboratories, IAC Interactive, Yext and more.
These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.
- The YouGov-Abbott Student Loan Impact Survey shows 87% of those in college or graduating this year with student debt say finding a company with a student loan benefit is important to them
- Partnership with NIH aims to increase understanding and accelerate the application of neurostimulation therapies
Now that our cash levels are even more flushed than before, we believe we have prudently acted for the uncertainty we face this week.
There is room here to take even more off the table and lock in some of the big gains.
ABBOTT PARK, Ill., May 7, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the UBS Global Healthcare Conference on Tuesday, May 21, 2019.
WORLD'S FIRST SMARTPHONE-COMPATIBLE IMPLANTABLE HEART MONITOR, ABBOTT'S CONFIRM Rx™ ICM OFFERS MORE ACCURATE DETECTION OF HEART RHYTHM DISORDERS
- WHO Prequalification approval allows Abbott to bring critical technology to more resource-limited settings
-- Academic, military and healthcare leaders have come together to conduct a scientifically rigorous clinical trial of a blood test in development for the brain
- Research found Abbott's High-Sensitive Troponin-I blood test may identify adults at risk of having a cardiac event, independent of other heart disease risk factors
We exited one position for a large gain and downgraded four others last week.
The Dow Jones Industrial Average finishes slightly down on sharp declines in shares of IBM and UnitedHealth.
We are ringing the register this afternoon and declaring victory on DHR ahead of earnings.
Jim discusses Abbott Laboratories' earnings release, his view of the Apple-Qualcomm settlement as it relates to the 5G cycle, several upcoming earnings reports, Anadarko Petroleum, UnitedHealth and much more!
Jim Cramer breaks down what he was watching when Abbott reported earnings Wednesday morning.
This was a very good quarter and the stock performance today is more of a reflection of the hatred for anything healthcare related as well as ABT's already premium valuation.
Abbott reports earnings above its own guidance and that of Wall Street analysts.
Qualcomm and Apple have settled their disputes, and Abbott and Netflix both released earnings.
Jim Cramer weighs in on Abbott's earnings, Qualcomm's dispute with Apple is over and Netflix's earnings.
- Sales and EPS growth exceed guidance; projects strong full-year outlook
China reported positive data, bolstering markets. Netflix had a beat on earnings, but faces fierce competition ahead. CSX is a thing of beauty.
U.S. stock futures rise Wednesday, following on from Tuesday's gains that were spurred on by generally solid earnings reports; Qualcomm surges after the chipmaker ends its long-running dispute with Apple; Netflix's second-quarter forecast disappoints Wall Street; Sprint and T-Mobile slide after a report says their proposed merger is getting resistance form the Justice Department.
They usually run their businesses well, too, Cramer says in revealing his '5 Rules for Trading Stocks During Earnings Season.'
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.